Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ZNTL
ZENTALIS PHARMACEUTICALS, INC.
NASDAQ
$3.80
▼ DOWN 2.06% (-0.08)

KEY STATISTICS

Market Cap$270.51 M
52w High$6.95
52w Low$1.21
Dividend Yield—
Frequency—
P/E-1.95
Volume695.39K
Shares Out.71.19M

COMPANY

LEADERSHIP

Julia Marie Eastland
CHIEF EXECUTIVE
Julia Marie Eastland

COMPENSATION 2026

Salary$700,000
Stock Awards$99,772
Incentive Plan Pay$441,000
All Other Comp.$2,984
Total$1,300,731

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 3, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
106

PRICE TARGET

Target High$10.00
Target Low$5.00
Target Median$10.00
Target Consensus$8.33

UPCOMING EARNINGS

DateNov 10, 2026
DayTuesday
Rev. Est.—
NOV
10
TUE

PRICE

$3.80 ▼ DOWN 2.06% (−$0.08)
$3.75$3.80$3.859:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.80

About Zentalis Pharmaceuticals, Inc.

https://www.zentalis.com ↗

Zentalis Pharmaceuticals is a clinical-stage biotech developing small molecule cancer therapies, including WEE1 inhibitor ZN-c3 and estrogen receptor degrader ZN-c5, with multiple trials targeting solid tumors, breast cancer, lymphoma, and lung ca...

INDUSTRY

Biotechnology

A PRODUCT ZENTALIS PHARMACEUTICALS, INC. IS KNOWN FOR

Azenosertib
Azenosertib

Azenosertib, a leading WEE1 inhibitor in late-stage trials for Cyclin E1-positive platinum-resistant ovarian cancer, is Zentalis Pharmaceuticals' flagship asset, aiming to provide a targeted, non-chemotherapy oral treatment for unmet medical needs.

COMPETITORS

COMPETITOR
APRE COMPARE
KURA COMPARE
PRLD COMPARE
RCUS COMPARE
REPL COMPARE

Revenue by Products

IconPRODUCTFY2024
Reportable Segment$67.42M

ETFS HOLDING THIS STOCK

ETFS HOLDING
57
LISTED HERE
12
RANKED BY POSITION SIZE
VTI
0.00% · 2.2M
XSU.TO
0.01% · 1.2M
FESM
0.03% · 572.7K
DFAS
0.00% · 154.5K
FSCC
0.14% · 131.8K
AVSC
0.02% · 127.0K
PRFZ
0.02% · 113.4K
R2SC.L
0.00% · 61.8K
XRSG.L
0.01% · 45.8K
RSSL
0.01% · 23.7K
URTY
0.00% · 2.0K
RESM
0.01% · 90

INSTITUTIONAL OWNERSHIP

SHARES OWNED
60.77%
HOLDERS
140
TOP 12 OF 140 · RANKED BY POSITION SIZE
Matrix Capital Management Company, LP
14.0M sh · $21.08M
Blackrock Inc.
4.8M sh · $19.71M
5am Venture Management, LLC
3.9M sh · $5.33M
Two Sigma Investments, LP
3.0M sh · $6.92M
Vanguard Group Inc
2.9M sh · $4.39M
Renaissance Technologies LLC
2.9M sh · $3.89M
Acadian Asset Management LLC
2.8M sh · $3.84M
Decheng Capital Management Iii (Cayman), LLC
2.1M sh · $42.12M
Citadel Advisors LLC
2.1M sh · $3.14M
D. E. Shaw & Co., Inc.
1.7M sh · $2.24M
Tang Capital Management LLC
1.6M sh · $2.34M
Bank Of America Corp /De/
1.5M sh · $2.34M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book3
Overall Score1

INSIDER TRADES

★
10 PERCENT OWNER
WALTERS GROUP
Purchase · 4.3M shares
2026-08-14
★
DIRECTOR
Johnson David Michael
Purchase · 57.1K shares
2026-06-16
★
DIRECTOR
Skvarka Jan
Purchase · 57.1K shares
2026-06-16
★
DIRECTOR
Walker Luke Nathaniel
Purchase · 57.1K shares
2026-06-16

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
EQUAL WEIGHT 1
2 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY Morgan Stanley EQUAL WEIGHT

SECTORS PEERS

PEERPRICE
IMMX$13.94COMPARE
STTK$7.04COMPARE
ARTV$11.09COMPARE
ALXO$2.00COMPARE
WHWK$4.62COMPARE
MGNX$4.13COMPARE
STRO$20.45COMPARE
DTIL$7.78COMPARE